NatureWise Biotech & Medicals Corporation (TPEX:4732)
Taiwan
· Delayed Price · Currency is TWD 23.60
+0.05 (0.21%)
Jun 6, 2025, 2:59 PM CST
TPEX:4732 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 224.32 | 160.14 | 228.59 | 249.8 | 306.92 | Upgrade
|
| Revenue Growth (YoY) | 40.08% | -29.94% | -8.49% | -18.61% | -0.18% | Upgrade
|
| Cost of Revenue | 104.12 | 72.76 | 98.66 | 103.62 | 123.48 | Upgrade
|
| Gross Profit | 120.2 | 87.38 | 129.93 | 146.19 | 183.44 | Upgrade
|
| Selling, General & Admin | 60.17 | 53.94 | 54.06 | 49.75 | 57.39 | Upgrade
|
| Research & Development | 72.07 | 30.01 | 49.48 | 69.46 | 68.14 | Upgrade
|
| Operating Expenses | 132.22 | 83.95 | 103.58 | 119.21 | 125.51 | Upgrade
|
| Operating Income | -12.02 | 3.43 | 26.35 | 26.98 | 57.92 | Upgrade
|
| Interest Expense | -0.1 | -0.05 | -0.04 | -0.03 | -0.06 | Upgrade
|
| Interest & Investment Income | 6.64 | 5.96 | 3.61 | 1.98 | 2.34 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.72 | 0.05 | -0.05 | 0.54 | -0.95 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.1 | 0.1 | -0.16 | 1.25 | 0.09 | Upgrade
|
| EBT Excluding Unusual Items | -3.65 | 9.49 | 29.71 | 30.72 | 59.35 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.44 | 0.31 | -0.08 | -0.02 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0 | - | - | Upgrade
|
| Pretax Income | -3.65 | 9.92 | 30.02 | 30.64 | 59.33 | Upgrade
|
| Income Tax Expense | -0.07 | -0.2 | - | -0.17 | -5.98 | Upgrade
|
| Earnings From Continuing Operations | -3.58 | 10.12 | 30.02 | 30.81 | 65.32 | Upgrade
|
| Minority Interest in Earnings | 4.48 | - | - | - | - | Upgrade
|
| Net Income | 0.9 | 10.12 | 30.02 | 30.81 | 65.32 | Upgrade
|
| Net Income to Common | 0.9 | 10.12 | 30.02 | 30.81 | 65.32 | Upgrade
|
| Net Income Growth | -91.14% | -66.29% | -2.54% | -52.83% | 64.54% | Upgrade
|
| Shares Outstanding (Basic) | 49 | 49 | 49 | 49 | 49 | Upgrade
|
| Shares Outstanding (Diluted) | 50 | 50 | 49 | 49 | 49 | Upgrade
|
| Shares Change (YoY) | -0.15% | 0.85% | 0.30% | -0.05% | 30.58% | Upgrade
|
| EPS (Basic) | 0.02 | 0.21 | 0.61 | 0.63 | 1.33 | Upgrade
|
| EPS (Diluted) | 0.02 | 0.20 | 0.61 | 0.62 | 1.32 | Upgrade
|
| EPS Growth | -90.90% | -67.17% | -1.75% | -53.03% | 26.05% | Upgrade
|
| Free Cash Flow | -2.91 | 61.9 | 13.85 | 33.72 | 54.61 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | 1.24 | 0.28 | 0.68 | 1.11 | Upgrade
|
| Dividend Per Share | - | 0.200 | 0.500 | 0.300 | 0.094 | Upgrade
|
| Dividend Growth | - | -60.00% | 66.67% | 218.13% | - | Upgrade
|
| Gross Margin | 53.58% | 54.56% | 56.84% | 58.52% | 59.77% | Upgrade
|
| Operating Margin | -5.36% | 2.14% | 11.53% | 10.80% | 18.87% | Upgrade
|
| Profit Margin | 0.40% | 6.32% | 13.13% | 12.33% | 21.28% | Upgrade
|
| Free Cash Flow Margin | -1.30% | 38.65% | 6.06% | 13.50% | 17.79% | Upgrade
|
| EBITDA | -5.57 | 9.84 | 37.15 | 38.01 | 65.54 | Upgrade
|
| EBITDA Margin | -2.48% | 6.14% | 16.25% | 15.22% | 21.35% | Upgrade
|
| D&A For EBITDA | 6.45 | 6.4 | 10.8 | 11.03 | 7.62 | Upgrade
|
| EBIT | -12.02 | 3.43 | 26.35 | 26.98 | 57.92 | Upgrade
|
| EBIT Margin | -5.36% | 2.14% | 11.53% | 10.80% | 18.87% | Upgrade
|
Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.